Nuclear receptor subfamily 1 group H member 4 (NR1H4)

Overview

Nuclear receptor subfamily 1 group H member 4, also known as farnesoid X receptor (FXR), is a ligand-activated nuclear receptor that functions as a key regulator of bile acid homeostasis and broader metabolic signaling. It is highly expressed in the liver and intestine, where it senses bile acids and coordinates transcriptional programs that influence bile acid synthesis, transport, lipid metabolism, and inflammatory responses. Because of this central role, FXR has become an important biomedical target in metabolic dysfunction–associated steatotic liver disease and Metabolic dysfunction associated steatohepatitis, as well as in related disorders involving obesity and dyslipidemia.

In therapeutic research, FXR is commonly studied as part of enterohepatic signaling axes that connect the gut microbiota, bile acid composition, and hepatic metabolism. Modulation of FXR signaling can alter downstream pathways such as FXR/CYP7A1/CYP8B1, FXR/SHP/SREBP-1c, and alternative bile acid synthesis routes involving CYP7B1 and CYP27A1. Recent studies have also examined FXR in combination with other targets, including HSD17B13 and the GLP-1 receptor, reflecting its role as a node in multi-target strategies for metabolic disease.

Recent Publications Summary

Recent studies have continued to position Nuclear receptor subfamily 1 group H member 4 (NR1H4, FXR) as a central regulator of bile acid signaling in metabolic disease and cancer. In diet-induced models of metabolic dysfunction-associated steatotic liver disease and Metabolic dysfunction associated steatohepatitis, FXR-targeting interventions were linked to improved hepatic steatosis and broader metabolic benefits, including altered bile acid homeostasis and gut microbiota remodeling42431962Jul42300918Jun42102281May41974237Apr41962186Apr. Several studies used multi-omics, bile acid profiling, transcriptomics, microbiome sequencing, and liver histology to connect FXR activity with enterohepatic circulation and inflammatory/fibrotic outcomes42431962Jul42300918Jun41974237Apr41962186Apr.

Multiple publications focused on natural products or microbiota-derived metabolites that modulate FXR signaling. Hawthorn procyanidin extract improved NAFLD in mice and HepG2 cells, with effects attributed in part to activation of hepatic FXR and restoration of bile acid homeostasis 42300918Jun. A bile salt hydrolase-producing Ligilactobacillus salivarius strain increased ursodeoxycholic acid, improved obesity-related phenotypes, and was reported to act as an intestinal FXR antagonist in the context of weight control 42092775May. HeDan capsules were also investigated in a rat MASLD model using metabolomics, gut microbiota analysis, and bile acid pathway studies to clarify whether their therapeutic effects involved bile acid metabolism regulation 41974237Apr. In another study, co-produced floridoside and isofloridoside from Pyropia haitanensis were evaluated in a murine MASH model, with mechanistic work including molecular docking, molecular dynamics, and western blotting to explore a gut microbiota–bile acid–FXR enterohepatic axis.

Drug discovery efforts further highlighted FXR as a therapeutic target for MASH. A non-carboxylic steroidal FXR agonist, compound 27, showed potent FXR agonism, oral bioavailability, and efficacy in preclinical fibrosis and MASH models, with reduced off-target MRGPRX4 activation compared with obeticholic acid 42102281May. Another program identified a first-in-class non-carboxylic dual FXR/HSD17B13 modulator that improved fatty liver, inflammation, and fibrosis in a WD + CCl4-induced MASH model 41962186Apr. These studies collectively support FXR-centered strategies for treating metabolic liver disease through combined effects on lipid metabolism, inflammation, fibrosis, and bile acid signaling 42102281May41962186Apr.

Beyond metabolic disease, NR1H4 was implicated in hepatocellular carcinoma immune evasion. A multi-omics study of peritumoral ductular reactions found cholic acid enrichment at the tumor margin and showed that it induced CD8+ T cell dysfunction via NR1H4-dependent PD1 upregulation; NR1H4 inhibition synergized with anti-PD1 therapy in murine models and suppressed tumor growth 41780844Mar. Together, these publications reinforce NR1H4 as a key bile acid-responsive nuclear receptor with roles spanning metabolic homeostasis, gut-liver axis regulation, and tumor immune modulation 41780844Mar41935584Apr.

What Changes, What Holds

1. FXR remains a central bile-acid node, but the new work broadens its disease reach and mechanistic readouts
REINFORCES These studies strengthen the baseline view that NR1H4/FXR sits at the center of enterohepatic control in metabolic liver disease, while adding more integrated evidence that its effects track with microbiota remodeling, bile acid composition, and inflammatory or fibrotic outcomes42431962Jul. The main change is not direction but confidence and scope: FXR-centered interventions continue to look relevant across MASLD/MASH models, with multi-omics approaches sharpening the same core model.

2. Microbiota-derived and natural compounds can push FXR signaling in opposite directions, so the axis is more context-dependent than the baseline implies
NEW DIRECTION Hawthorn-derived and algal products fit the established idea that FXR is a druggable bile-acid sensor, but the probiotic and metabolite findings complicate the picture by showing that intestinal FXR may be antagonized in one obesity-control setting while hepatic FXR is activated in another 42300918Jun42092775May. That does not overturn the baseline, which already allows enterohepatic modulation, but it does show that “FXR modulation” is not uniformly beneficial and may depend on tissue, ligand source, and metabolic context.

3. FXR-centered drug discovery is moving from proof of concept toward more selective therapeutic design
REINFORCES The new agonist and dual-modulator programs extend the baseline therapeutic framing by showing that FXR can still be exploited for MASH while trying to avoid liabilities seen with earlier agents 42102281May41962186Apr. What matters is not a new biological role but a refinement of how the target may be used: the work supports FXR as a continuing scaffold for anti-steatotic, anti-inflammatory, and anti-fibrotic strategies, with selectivity and off-target control becoming central design goals.

4. NR1H4 now appears to shape antitumor immunity, not just metabolic signaling
NEW DIRECTION The cancer study adds a role that the baseline does not cover: bile-acid–driven NR1H4 activity can suppress CD8+ T-cell function and promote immune evasion in hepatocellular carcinoma 41780844Mar. That leaves the metabolic account intact but expands the receptor’s significance into tumor immunology, suggesting that FXR inhibition could have context-specific value beyond liver metabolism and that bile acid signaling may be a therapeutic liability in the tumor microenvironment 41780844Mar41935584Apr.

Overview update candidates: intestinal versus hepatic FXR context dependence; NR1H4 involvement in hepatocellular carcinoma immune evasion.